
MRK · Merck & Co., Inc.
2708.00
MXNUnlock stock Insights
Create a free account to unlock price targets, recommendations, and commentary.
Overview
Market Cap
MXN$6.69T
PE
13.50
EV/EBITDA
9.5
DIV Yield
3.3%
Payout Ratio
45%
MQV Rating
5Very Weak
As at 15/10/2026 12:00:00 AM
Price Chart
Description
- All-Companies
- Near 52 Week High
- Near Resistance
Key Fundamentals
EPS 3 yr Growth
21.40%
EBITDA Margin
45.20%
Operating Cashflow
$316,269m
Free Cash Flow Return
18.10%
ROIC
20.00%
Interest Coverage
21.60
Quick Ratio
1.30
Performance
52 weeks range
Low 1531 - 2736.62
Trade Value (12mth)
US$71,213.00
1 week
7.4%
1 month
10.35%
YTD
42.9%
1 year
72.81%
All time high
2736.62
Additional Data
Shares Outstanding (Fully Diluted)
2,470m
HALO Sector
Healthcare
Next Company Report Date
N/A
Next Ex Dividend Date
15-Sep-26
Next Dividend Pay Date
07-Oct-26
Reporting Currency
MXN
Short Sell (% of issue)
0.00
Health Scores
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Very Strong
Halo Model
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Weak
Growth
Earnings
Very Weak
Dividends
Very Weak
Quality
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Valuation
Key Stakeholders
| Name | Title |
| OrbiMed Advisors Private Equity | Subsidiary |
| Employees Provident Fund (Investment Management) | Operating Division |
| Robert M. Davis | Individual |
| Sanat Chattopadhyay | Individual |
| Richard R. DeLuca | Individual |